Abstract
Only approximately 12% of drug candidates in clinical trials will reach the market due to unpredicted liabilities in pharmacokinetics, pharmacodynamics, efficacy, and toxicity ([1][1]). Novel techniques, including organs-on-chips, are critical to accelerate drug development and better predict drug
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Clinical journal of the American Society of Nephrology : CJASN
Paper Title
Journal
Date
